Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of roflumilast for persistent post-stroke cognitive impairment
NL-OMON52276Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast, sponsored by Maastricht University. Started Jul 2021; status: completed.
02
Drugs
roflumilast
Beyond the preview
Go deeper on NL-OMON52276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52276.